SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Northwest Biotherapeutics Inc.
NWBO 0.250+4.2%Oct 31 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: John McCarthy12/27/2007 7:49:30 AM
   of 759
 
Northwest Biotherapeutics starts clinical trial for ovarian cancer

December 27, 2007: 04:37 AM EST

LONDON, Dec. 27, 2007 (Thomson Financial delivered by Newstex) -- Northwest Biotherapeutics (OTCBB:NWBO) Inc said it has started a phase I/II clinical trial for ovarian cancer in at least 30 patients, using its personalised immunotherapy - DCVax-L - for recurrent ovarian cancer.

The biotechnology company said the trial involves two sequential studies, and comprises an innovative combination of multiple treatment modalities.

The treatment is complemented by administration of low doses of certain existing approved drugs to help improve the immune system environment, as well as by adoptive transfer of patients' DCVax-L primed T cells, it said.

DCVax-L is made from a patient's own dendritic cells and the 'antigens' (biomarkers) from the patient's own tumour tissue which has been surgically removed as part of the standard of care, Northwest added.

Copyright Thomson Financial News Limited 2007. All rights reserved.

The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.

Newstex ID: AFX-0013-21907596

money.cnn.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext